Alvine Pharmaceuticals (Asstes) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Alvine Pharmaceuticals (Asstes) General Information
Description
The assets include ALV003, a mixture of two gluten-specific recombinant proteases engineered to digest gluten and to treat patients with celiac disease. Latiglutenase (formerly known as ALV003 and renamed IMGX-003) is an orally administered mixture of two recombinant gluten-specific proteases including glutamine-specific cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP) to treat celiac disease.
Contact Information
Corporate Office
- Shoreway Road
- Suite B
- San Carlos, CA
- United States
Corporate Office
- Shoreway Road
- Suite B
- San Carlos, CA
- United States
Alvine Pharmaceuticals (Asstes) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alvine Pharmaceuticals (Asstes) FAQs
-
Where is Alvine Pharmaceuticals (Asstes) headquartered?
Alvine Pharmaceuticals (Asstes) is headquartered in San Carlos, CA.
-
What industry is Alvine Pharmaceuticals (Asstes) in?
Alvine Pharmaceuticals (Asstes)’s primary industry is Buildings and Property.
-
Is Alvine Pharmaceuticals (Asstes) a private or public company?
Alvine Pharmaceuticals (Asstes) is a Private company.
-
What is Alvine Pharmaceuticals (Asstes)’s current revenue?
The current revenue for Alvine Pharmaceuticals (Asstes) is .
-
When was Alvine Pharmaceuticals (Asstes) acquired?
Alvine Pharmaceuticals (Asstes) was acquired on 15-Mar-2016.
-
Who acquired Alvine Pharmaceuticals (Asstes)?
Alvine Pharmaceuticals (Asstes) was acquired by ImmunogenX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process